Source - RNS
RNS Number : 5637L
The MedicX Fund Limited
03 October 2016


Press Release

For immediate release                                                                                    

3 October 2016


MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")


Allotment of scrip shares to Directors of the Company



Members of the Company's Board of Directors elected to participate in the Company's scrip dividend scheme in respect of the September 2016 dividend for the quarter ended 30 June 2016, and accordingly acquired ordinary shares of no par value in the Company (the "Shares") as disclosed in the table below. The Shares were sold out of treasury by the Company at the previously advised scrip calculation price of 90.55 pence per share.



Shares Acquired

Total Shares Held

Percentage Holding

David Staples (Chairman)




Shelagh Mason




John Hearle





The Shares were acquired on 30 September 2016 and rank pari passu with the Company's existing ordinary shares.


The Directors detailed above, who elected to participate in the Company's scrip dividend scheme, did so under an election mandate which remains in place until revoked. 


Copies of the documents relating to the Scrip Dividend Alternative are available for inspection through the National Storage Mechanism (




For further information please contact:


MedicX Fund                                                                  +44 (0) 1481 723 450

David Staples, Chairman


Octopus Healthcare Group                                               +44 (0) 20 3142 4820

Mike Adams, Chief Executive Officer


Buchanan                                                                      +44 (0) 20 7466 5000

Charles Ryland/Vicky Hayns



Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", "MedicX Fund", "the Fund" or "the Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 152 properties.


The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1 billion of healthcare investments across a number of platforms, with a focus on four core areas: GP surgeries, care homes, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £5.5 billion of funds for more than 50,000 retail and institutional investors.

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is  Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.


This information is provided by RNS
The company news service from the London Stock Exchange